AU2006328607B2 - Treatment of drug-resistant tumors - Google Patents

Treatment of drug-resistant tumors Download PDF

Info

Publication number
AU2006328607B2
AU2006328607B2 AU2006328607A AU2006328607A AU2006328607B2 AU 2006328607 B2 AU2006328607 B2 AU 2006328607B2 AU 2006328607 A AU2006328607 A AU 2006328607A AU 2006328607 A AU2006328607 A AU 2006328607A AU 2006328607 B2 AU2006328607 B2 AU 2006328607B2
Authority
AU
Australia
Prior art keywords
topoisomerase
drug
treatment
tumor
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006328607A
Other languages
English (en)
Other versions
AU2006328607A1 (en
Inventor
Claudio Pisano
Loredana Vesci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2006328607A1 publication Critical patent/AU2006328607A1/en
Application granted granted Critical
Publication of AU2006328607B2 publication Critical patent/AU2006328607B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2006328607A 2005-12-21 2006-12-13 Treatment of drug-resistant tumors Ceased AU2006328607B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027997.5 2005-12-21
EP05027997 2005-12-21
PCT/EP2006/069666 WO2007071603A1 (en) 2005-12-21 2006-12-13 Treatment of drug-resistant tumors

Publications (2)

Publication Number Publication Date
AU2006328607A1 AU2006328607A1 (en) 2007-06-28
AU2006328607B2 true AU2006328607B2 (en) 2012-04-19

Family

ID=35911064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006328607A Ceased AU2006328607B2 (en) 2005-12-21 2006-12-13 Treatment of drug-resistant tumors

Country Status (19)

Country Link
US (1) US7888368B2 (enExample)
EP (1) EP1962850B1 (enExample)
JP (1) JP5657205B2 (enExample)
KR (1) KR101366868B1 (enExample)
CN (1) CN101340910B (enExample)
AT (1) ATE548038T1 (enExample)
AU (1) AU2006328607B2 (enExample)
BR (1) BRPI0620209A2 (enExample)
CA (1) CA2631868C (enExample)
CY (1) CY1112814T1 (enExample)
DK (1) DK1962850T3 (enExample)
EA (1) EA016487B1 (enExample)
ES (1) ES2382819T3 (enExample)
HR (1) HRP20120359T1 (enExample)
PL (1) PL1962850T3 (enExample)
PT (1) PT1962850E (enExample)
RS (1) RS52272B (enExample)
SI (1) SI1962850T1 (enExample)
WO (1) WO2007071603A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
JP5765937B2 (ja) * 2007-08-01 2015-08-19 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 小児腫瘍の治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242457B1 (en) * 1999-03-09 2001-06-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242457B1 (en) * 1999-03-09 2001-06-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity

Also Published As

Publication number Publication date
CN101340910A (zh) 2009-01-07
EP1962850A1 (en) 2008-09-03
HRP20120359T1 (hr) 2012-06-30
JP2009520754A (ja) 2009-05-28
CN101340910B (zh) 2012-12-12
WO2007071603A1 (en) 2007-06-28
DK1962850T3 (da) 2012-06-18
ES2382819T3 (es) 2012-06-13
EA016487B1 (ru) 2012-05-30
US7888368B2 (en) 2011-02-15
PL1962850T3 (pl) 2012-07-31
AU2006328607A1 (en) 2007-06-28
CA2631868C (en) 2014-02-11
HK1124776A1 (zh) 2009-07-24
CA2631868A1 (en) 2007-06-28
BRPI0620209A2 (pt) 2011-11-01
PT1962850E (pt) 2012-05-21
ATE548038T1 (de) 2012-03-15
JP5657205B2 (ja) 2015-01-21
EP1962850B1 (en) 2012-03-07
CY1112814T1 (el) 2016-02-10
EA200870073A1 (ru) 2009-12-30
RS52272B (sr) 2012-10-31
KR101366868B1 (ko) 2014-02-21
KR20080078055A (ko) 2008-08-26
SI1962850T1 (sl) 2012-06-29
US20080312265A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
US6352996B1 (en) Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6218399B1 (en) Derivatives of camptothecin and methods of treating cancer using these derivatives
Verschraegen et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
US20090181997A1 (en) Therapeutic cancer treatments
JPH07501079A (ja) 組合せ化学療法
Pantazis Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments.
Kawato et al. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats
US20100222287A1 (en) Therapeutic Cancer Treatments
CN112672789A (zh) 用于治疗癌症的5-乙酰氨基甲基-噁唑烷酮衍生物
EP2153821A1 (en) Oral formulations of camptothecin derivatives
AU2006328607B2 (en) Treatment of drug-resistant tumors
De Cesare et al. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series
US8853233B2 (en) Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
Sampath et al. Camptothecin analogs in malignant gliomas: comparative analysis and characterization
TWI472330B (zh) 用於癌症治療之增敏劑、套組及用途
Boisseau et al. Drug Evaluation: Oncologic, Endocrine & Metabolic: Irinotecan (CPT-11): Current status and perspectives
HK1124776B (en) Treatment of drug-resistant tumors
Hageman et al. Case study: Irinotecan (CPT-11), a water-soluble prodrug of SN-38
Das et al. Berzosertib. ATR kinase inhibitor, Treatment of solid tumors
Ahn et al. CKD-602
JPH03502806A (ja) ガンの処理
NATELSON et al. Phase I Clinical and Pharmacological Studies of 20-(S)-Camptothecin and 20-(S)-9-Nitrocamptothecin as Anticancer Agents zyxwvutsrqpon

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired